HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- ‘Overdiagnosis’ may not fully explain rise in pediatric thyroid cancer incidence Jennifer R. Southall
-
- Should suspicious pediatric thyroid nodules smaller than 1 cm on ultrasound undergo biopsy?
- An unspoken cost of treatment: Addressing the sexual health needs of AYAs with cancer Stacy Whiteside, APRN, MS, CPNP-AC/PC, CPON
- Adjuvant atezolizumab extends DFS in early-stage NSCLC Ryan Lawrence
- American Cancer Society’s first female CEO discusses goals, lessons learned amid pandemic Talitha Bennett
- Cervical cancer incidence declines as rates of other HPV-associated cancers rise Ryan Lawrence
- Dabrafenib-trametinib combination active in BRAF V600E-mutant glioma Mark Leiser
- Dual checkpoint blockade improves PFS as first-line treatment of advanced melanoma Alexandra (Sasha) Todak
- Pegcetacoplan approved for paroxysmal nocturnal hemoglobinuria
-
- Zanubrutinib receives priority review for pretreated marginal zone lymphoma
- Financial toxicity associated with poorer head and neck cancer survival outcomes Ryan Lawrence
- Immune checkpoint inhibitors linked to high VTE risk Jennifer R. Southall
- Inpatient hospitalization, mortality high among patients with cancer, COVID-19 Mark Leiser
- Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer Jennifer R. Southall
- Roswell Park appoints immuno-oncology chief
- Rutgers Cancer Institute of New Jersey appoints neuro-oncology program director
- Dana-Farber appoints chief clinical access and equity officer
-